IBA Molecular North America to become Zevacor Pharma

DULLES, Va., Nov. 30, 2015 /PRNewswire/ -- IBA Molecular North America, Inc. (IBAMNA), a U.S. leader in the manufacture and distribution of radiopharmaceuticals, announced that as of January 1, 2016, it will do business as Zevacor Pharma, Inc. (Zevacor Pharma). The decision to rebrand the company reflects a refined vision for the future of the firm as well as its close relationship with Zevacor Molecular.  Both IBAMNA and Zevacor Molecular are owned by Illinois Health and Science (IHS).

"We will continue our commitment to deliver better diagnosis and care through innovation," noted Peter Burke, Vice President Sales and Marketing, IBAMNA. "The new name - Zevacor Pharma - reflects our goal of broadening the impact of nuclear medicine and molecular imaging through both existing and new radiopharmaceuticals."  

"The company has built a solid reputation for producing quality radiopharmaceuticals," said Peter Webner, interim Executive Vice President and COO, IBAMNA. "Now we are leading the industry in developing the next generation of molecular imaging and therapeutic products. Zevacor Pharma and its sister company Zevacor Molecular will be providing the nuclear medicine community with innovative compounds for today and the future."

IBAMNA was originally named for its onetime parent company Ion Beam Applications S.A. (Louvain-la-Neuve, Belgium) and operated as its North American subsidiary. IBAMNA was acquired in July 2015 by Illinois Health and Science (IHS), a non-profit healthcare system based in Decatur, Illinois. The IHS family of companies also includes Decatur Memorial Hospital and Integrated Health Network.

About IBA Molecular North America, Inc.
IBA Molecular North America, Inc. (IBAMNA) is a leading developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging in the U.S.  The company's expertise in radiolabelling services and scalable manufacturing from pre-clinical to full commercial production is helping broaden the impact of nuclear medicine and molecular imaging/therapy. IBAMNA's parent company is Illinois Health and Science (IHS), a non-profit healthcare system that also owns Decatur (IL) Memorial Hospital, Integrated Health Network and Zevacor Molecular. Zevacor Molecular and IBAMNA, as affiliated radiopharmaceutical manufacturers, are committed to the IHS mission of enhancing the span, experience and quality of human life through improved patient care and outcomes.

For more information, please visit www.ibamolecular.com

SOURCE IBA Molecular North America, Inc.

Related Links

http://www.ibamolecular.com